CD8A and cancer: This inhibitor reduced primary tumor growth and liver metastasis by blocking cancer associated fibroblast (CAF)- derived TGF-β signaling in the TME, and increasing the infiltration and function of CD8+ CTLs or CD4+ T-helper cells [230].